Millipore's Anti-Bak (N-terminus) polycloncal antibody is designed to accelerate programmed cell death by binding to, and antagonizing the repressor Bcl-2 or its adenovirus homolog E1B 19k protein.
Bak or Bcl2 homologous antagonist is a member of the Bcl2 family of proteins.
The Bcl-2 related proteins interact with one another through the formation
of homo and heterodimers. The susceptibility of cells to apoptotic stimuli
is thought to be controlled by the relative ratios of the different Bcl2
family proteins. Bak has been demonstrated to accelerate the rate of
apoptosis in growth factor deprived murine lymphoid, neuronal and
fibroblastic cell lines. This protein localizes to mitochondria, and
functions to induce apoptosis. It interacts with and accelerates the opening
of the mitochondrial voltage-dependent anion channel, which leads to a loss
in membrane potential and the release of cytochrome c. Bak also interacts
with the tumor suppressor P53 after exposure to cell stress.
Key Applications: Western Blotting, Immunohistochemistry, Immunocytochemistry, Immunoprecipitation
Millipore is a life science company providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, the company collaborates with customers to confront the world’s challenging human health issues. From research to development to production, the company's scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with 6,000 employees in 47 countries worldwide.